

DCCG'S NATIONALE RETNINGSLINIER FOR DIAGNOSTIK OG BEHANDLING AF KOLOREKTAL CANCER		
<b>Behandling af metastaserende kolorektal cancer (mKRC)</b>		
Forfattere: PP, CQ	Gælder fra: 9. April 2015	Gælder til:

1. The Meta-Analysis Group. Modulation of Fluorouracil by Leucovorin in Patients With Advanced Colorectal Cancer: An Updated Meta-Analysis. *J Clin Oncol* 2004; 22: 3766-75.
2. de Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. *J Clin Oncol* 1997; 15: 808-15.
3. Meyerhardt JA, Mayer RJ. Systemic Therapy for Colorectal Cancer. *N Engl J Med* 2005; 352: 476-87.
4. Kohne CH, Wils J, Lorenz M et al. Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. *J Clin Oncol* 2003; 21: 3721-8.
5. Glimelius B, Jakobsen A, Graf W et al. Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. *Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Eur J Cancer* 1998; 34: 674-8.
6. Douillard JY, Hoff PM, Skillings JR et al. Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer. *J Clin Oncol* 2002; 20: 3605-16.
7. Hoff PM, Ansari R, Batist G et al. Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study. *J Clin Oncol* 2001; 19: 2282-92.
8. Van Cutsem E, Twelves C, Cassidy J et al. Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study. *J Clin Oncol* 2001; 19: 4097-106.
9. de Gramont A, Figer A, Seymour M et al. Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. *J Clin Oncol* 2000; 18: 2938-47.
10. Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial. *J Clin Oncol* 2003; 21: 2059-69.
11. Saltz LB. Irinotecan in the first-line treatment of colorectal cancer. *Oncology (Williston Park)* 1998; 12: 54-8.
12. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. *Lancet* 2000; 355: 1041-7.
13. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer. *N Engl J Med* 2000; 343: 905-14.

DCCG'S NATIONALE RETNINGSLINIER FOR DIAGNOSTIK OG BEHANDLING AF KOLOREKTAL CANCER		
<b>Behandling af metastaserende kolorektal cancer (mKRC)</b>		
Forfattere: PP, CQ	Gælder fra: 9. April 2015	Gælder til:

14. Scheithauer W, Rosen H, Kornek GV et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. *BMJ* 1993; 306: 752-5.
15. Palliative chemotherapy for advanced or metastatic colorectal cancer. Colorectal Meta-analysis Collaboration. *Cochrane Database Syst Rev* 2000; CD001545.
16. Giacchetti S, Perpoint B, Zidani R et al. Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil-Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer. *J Clin Oncol* 2000; 18: 136-47.
17. Goldberg RM, Sargent DJ, Morton RF et al. A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer. *J Clin Oncol* 2004; 22: 23-30.
18. Kohne CH, Van Cutsem E, Wils J et al. Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. *J Clin Oncol* 2005; 23: 4856-65.
19. Tournigand C, Andre T, Achille E et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. *J Clin Oncol* 2004; 22: 229-37.
20. Comella P, Massidda B, Filippelli G et al. Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFUFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFUFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial. *Ann Oncol* 2005; 16: 878-86.
21. Kalofonos HP, Aravantinos G, Kosmidis P et al. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. *Ann Oncol* 2005; 16: 869-77.
22. Folprecht G, Seymour MT, Saltz L et al. Irinotecan/Fluorouracil Combination in First-Line Therapy of Older and Younger Patients With Metastatic Colorectal Cancer: Combined Analysis of 2,691 Patients in Randomized Controlled Trials. *J Clin Oncol* 2008; 26: 1443-51.
23. Sargent DJ, Kohne CH, Sanoff HK et al. Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer. *J Clin Oncol* 2009; 27: 1948-55.
24. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. *N Engl J Med* 2004; 350: 2335-42.
25. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer. *J Clin Oncol* 2003; 21: 60-5.
26. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic

DCCG'S NATIONALE RETNINGSLINIER FOR DIAGNOSTIK OG BEHANDLING AF KOLOREKTAL CANCER		
<b>Behandling af metastaserende kolorektal cancer (mKRC)</b>		
Forfattere: PP, CQ	Gælder fra: 9. April 2015	Gælder til:

- Colorectal Cancer: A Randomized Phase III Study. *J Clin Oncol* 2008; 26: 2013-9.
27. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200. *J Clin Oncol* 2007; 25: 1539-44.
28. Bennouna, J, Sastre, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. *Lancet Oncol* 2013; 14: 29–37.
29. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen. *J Clin Oncol* 2012; 30: 3499-506.
30. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. *N Engl J Med* 2009; 360: 1408-17.
31. Van Cutsem E, Kohne CH, Láng I et al. Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. *J Clin Oncol* 2011; 29: 2011-9.
32. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer. *J Clin Oncol* 2009; 27: 663-71.
33. Douillard JY, Siena S, Cassidy J et al. Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. *J Clin Oncol* 2010; 28: 4697-705.
34. Peeters M, Price TJ, Cervantes As et al. Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. *J Clin Oncol* 2010; 28: 4706-13.
35. Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer. *J Clin Oncol* 2008; 26: 2311-9.
36. Maughan TS, Adams RA, Smith CG et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. *Lancet* 2011; 377: 2103-14.
37. Tveit KM, Guren T, Glimelius B et al. Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study. *J Clin Oncol* 2012; 30: 1755-62.
38. Hecht JR, Mitchell E, Chidiac T et al. A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer. *J Clin Oncol* 2009; 27: 672-80.

DCCG'S NATIONALE RETNINGSLINIER FOR DIAGNOSTIK OG BEHANDLING AF KOLOREKTAL CANCER		
<b>Behandling af metastaserende kolorektal cancer (mKRC)</b>		
Forfattere: PP, CQ	Gælder fra: 9. April 2015	Gælder til:

39. Tol J, Koopman M, Cats A et al. Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer. *N Engl J Med* 2009; 360: 563-72.
40. Saltz LB, Lenz HJ, Kindler HL et al. Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study. *J Clin Oncol* 2007; 25: 4557-61.
41. Chibaudel B, Maindrault-Goebel F, Lledo G et al. Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study. *J Clin Oncol* 2009; 27: 5727-33.
42. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer--A GERCOR Study. *J Clin Oncol* 2006; 24: 394-400.
43. Wasan, H., Adams, R. A., Wilson, R. H., Pugh, C. A., Fisher, D., Madi, A., Sizer, B., Butler, R., Meade, A. M., and Maughan, T. S. Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC) - Results of the Two-arm Phase II Randomised MRC COIN-B Trial Abstr. 6006
44. Labianca R, Sobrero A, Isa L et al. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised GISCAD trial. *Ann Oncol* 2011; 22: 1236-42.
45. Grothey A, Sargent D, Goldberg RM et al. Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment. *J Clin Oncol* 2004; 22: 1209-14.
46. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the Treatment of Colorectal Cancer. *N Engl J Med* 2007; 357: 2040-8.
47. Van Cutsem E, Peeters M, Siena S et al. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer. *J Clin Oncol* 2007; 25: 1658-64.
48. Amado RG, Wolf M, Peeters M et al. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. *J Clin Oncol* 2008; 26: 1626-34.
49. Cunningham D, Humblet Y, Siena S et al. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. *N Engl J Med* 2004; 351: 337-45.
50. Pfeiffer P, Nielsen D, Yilmaz M et al. Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. *Acta Oncol* 2007; 46: 697-701.
51. De Roock W, Piessevaux H, De Schutter J et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. *Ann Oncol* 2008; 19: 508-15.
52. Jensen, B. V., Schou, J. V, Johannesen, H. H, Christensen, I. J., Nielsen, D., Johansen, J. S, Hogdall, E. V., Larsen, O., Yilmaz, M., and Pfeiffer, P. Cetuximab every second week with irinotecan in patients with metastatic colorectal cancer refractory to 5-FU, oxaliplatin, and irinotecan: KRAS mutation status and efficacy ASCO 2010 abstr 3573

DCCG'S NATIONALE RETNINGSLINIER FOR DIAGNOSTIK OG BEHANDLING AF KOLOREKTAL CANCER		
<b>Behandling af metastaserende kolorektal cancer (mKRC)</b>		
Forfattere: PP, CQ	Gælder fra: 9. April 2015	Gælder til:

53. Pfeiffer P, Nielsen D, Bjerregaard J et al. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. *Ann Oncol* 2008; 19: 1141-5.
54. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013; 381: 303-12.
55. Larsen FO, Boisen MKI, Fromm AL et al. Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer. *Acta Oncol* 2011; 51: 231-3.
56. Larsen FO, Pfeiffer P, Nielsen D et al. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer. *Acta Oncol* 2011; 50: 574-7.
57. Qvortrup C, Jensen BV, Jorgensen TL et al. Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer. *Acta Oncol* 2010; 49: 833-6.
58. Abdalla EK, Vauthey JN, Ellis LM et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. *Ann Surg* 2004; 239: 818-25.
59. Garcea G, Ong SL, Maddern GJ. Inoperable colorectal liver metastases: a declining entity? *Eur J Cancer* 2008; 44: 2555-72.
60. Sanoff HK, Sargent DJ, Campbell ME et al. Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741. *J Clin Oncol* 2008; 26: 5721-7.
61. Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. *Ann Surg* 1999; 230: 309-18.
62. Park IJ, Kim HC, Yu CS et al. Radiofrequency ablation for metachronous liver metastasis from colorectal cancer after curative surgery. *Ann Surg Oncol* 2008; 15: 227-32.
63. Reuter NP, Woodall CE, Scoggins CR et al. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent? *J Gastrointest Surg* 2009; 13: 486-91.
64. Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. *Lancet* 2008; 371: 1007-16.
65. Sorbye H, Mauer M, Gruenberger T et al. Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983). *Ann Surg* 2012.
66. Mityr E, Fields ALA, Bleiberg H et al. Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials. *J Clin Oncol* 2008; 26: 4906-11.
67. Adam R, Avisar E, Ariche A et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. *Ann Surg Oncol* 2001; 8: 347-53.

DCCG'S NATIONALE RETNINGSLINIER FOR DIAGNOSTIK OG BEHANDLING AF KOLOREKTAL CANCER		
<b>Behandling af metastaserende kolorektal cancer (mKRC)</b>		
Forfattere: PP, CQ	Gælder fra: 9. April 2015	Gælder til:

68. Folprecht G, Grothey A, Alberts S et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. *Ann Oncol* 2005; 16: 1311-9.
69. Falcone A, Ricci S, Brunetti I et al. Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest. *J Clin Oncol* 2007; 25: 1670-6.
70. Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. *The Lancet* 2007; 370: 135-42.
71. Seymour MT, Maughan TS, Ledermann JA et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. *Lancet* 2007; 370: 143-52.
72. Tjandra JJ, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. *Dis Colon Rectum* 2007; 50: 1783-99.
73. Ye L, Liu, T, Ren L, et al. Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients With KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases. *J Clin Oncol* 2013; e-pub
74. Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. *Lancet Onc* 2013; e-pub September.
75. Douillard J-Y, Oliner KS, Siena S, et al. Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. *NEJM* 2013 369: 1023-34.
76. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Onc* 2010; 11: 753-62.
77. Nielsen DL, Palshof JA, Larsen FO, et al: A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. *Cancer Treat Rev* 2014; 40: 701-15.
78. Mayer RJ, Van CE, Falcone A, et al: Randomized trial of TAS-102 for refractory metastatic colorectal cancer *N Engl J Med* 2015; 372: 1909-19.
79. Tabernero J, Yoshino T, Cohn AL, et al: Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. *Lancet Oncol* 2015; 16: 499-508.
80. Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Sugimoto N, Tsuji Y, Moriwaki T, Esaki T, Hamada C, Tanase T, Ohtsu A. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. *Lancet Oncol* 2012; 13: 993-1001.

DCCG'S NATIONALE RETNINGSLINIER FOR DIAGNOSTIK OG BEHANDLING AF KOLOREKTAL CANCER		
<b>Behandling af metastaserende kolorektal cancer (mKRC)</b>		
Forfattere: PP, CQ	Gælder fra: 9. April 2015	Gælder til:

81. Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a random-ized, multicenter phase II study of panitumumab plus modifiedfluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumabplus mFOLFOX6 in patients with previously untreated, unresectable,wild-type KRAS exon 2 metastatic colorectal cancer. *J Clin Oncol*2014; 32: 2240–7.
82. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI pluscetuximab versus FOLFIRI plus bevacizumab as first-line treatmentfor patients with metastatic colorectal cancer (FIRE-3): a randomised,open-label, phase 3 trial. *Lancet Oncol* 2014; 15: 1065–75.
83. Khattak MA, Martin H, Davidson A, Phillips M. Role of First-Line Anti Epidermal Growth Factor Receptor Therapy Compared With Anti-Vascular Endothelial Growth Factor Therapy in Advanced Colorectal Cancer: A Meta-Analysis of Randomized Clinical Trials. *Clinical Colorectal Cancer* 2015; 14: 81-90.
84. Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2015; 16: 619-29.